Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).

被引：48
|
作者：
Sharma, Padmanee
Pachynski, Russell Kent
Narayan, Vivek
Flechon, Aude
Gravis, Gwenaelle
Galsky, Matt D.
Mahammedi, Hakim
Patnaik, Akash
Subudhi, Sumit Kumar
Ciprotti, Marika
Duan, Tao
Saci, Abdel
Hu, Sarah
Han, G. Celine
Fizazi, Karim
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Washington Univ, Sch Med, St Louis, MO USA
[3] Penn Med Abramson Canc Ctr, Philadelphia, PA USA
[4] Ctr Leon Berard, Lyon, France
[5] Inst Paoli Calmettes, Med Oncol, Marseille, France
[6] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA
[7] Ctr Jean Perrin, Clermont Ferrand, France
[8] Univ Chicago, Ctr Comprehens Canc, Chicago, IL 60637 USA
[9] Bristol Myers Squibb, Princeton, NJ USA
[10] Gustave Roussy, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.142
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
142
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase I/II trial of enzalutamide (Enz) plus mifepristone (Mif) for metastatic castration-resistant prostate cancer (mCRPC)
    Serritella, Anthony
    Shevrin, Daniel H.
    Heath, Elisabeth I.
    Wade, James Lloyd
    Martinez, Elia
    Karrison, Theodore
    Stadler, Walter Michael
    Szmulewitz, Russell Zelig
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [22] Results of a phase II study of sunitinib (SU) maintenance after response to docetaxel in metastatic castration-resistant prostate cancer (mCRPC)
    Eigl, Bernhard J.
    Eliasziw, Misha
    North, Scott A.
    Trudeau, Marc G.
    Winquist, Eric
    Chi, Kim N.
    Ruether, Joseph D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [23] STARVE-PC: Biomarker-driven phase 2 study of ipilimumab plus nivolumab for AR-V7-expressing metastatic castration-resistant prostate cancer (mCRPC).
    Boudadi, Karim
    Suzman, Daniel L.
    Luber, Brandon
    Wang, Hao
    Silberstein, John L.
    Taylor, Maritza N.
    Sullivan, Rana
    Dowling, Donna
    Harb, Rana
    Dittamore, Ryan Vance
    Meeker, Alan
    Luo, Jun
    Drake, Charles G.
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] Preliminary phase II results of the CYPIDES study of ODM208 in metastatic castration-resistant prostate (mCRPC) cancer patients
    Fizazi, K.
    Bernard-Tessier, A.
    Barthelemy, P.
    Utriainen, T.
    Roubaud, G.
    Flechon, A.
    van der Voet, J. C. M.
    Mescam, G. Gravis
    Ratta, R.
    Jones, R. H.
    Parikh, O. A.
    Tanner, M. M. E.
    Garratt, C.
    Nevalaita, L.
    Pohjanjousi, P.
    Ikonen, T.
    Antonarakis, E. S.
    Cook, N.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1165 - S1165
  • [25] Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC)
    Beer, T. M.
    Slovin, S. F.
    Higano, C. S.
    Tejwani, S.
    Dorff, T. B.
    Stankevich, E.
    Lowy, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] Nivolumab plus docetaxel in patients with chemotherapy- nai spacing diaeresis ve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial
    Fizazi, Karim
    Gonzalez Mella, Pablo
    Castellano, Daniel
    Minatta, Jose N.
    Rezazadeh Kalebasty, Arash
    Shaffer, David
    Vazquez Limon, Juan C.
    Sanchez Lopez, Hector M.
    Armstrong, Andrew J.
    Horvath, Lisa
    Bastos, Diogo A.
    Amin, Neha P.
    Li, Jia
    Unsal-Kacmaz, Keziban
    Retz, Margitta
    Saad, Fred
    Petrylak, Daniel P.
    Pachynski, Russell K.
    EUROPEAN JOURNAL OF CANCER, 2022, 160 : 61 - 71
  • [27] A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Werner, Lillian
    Erlander, Mark G.
    Ridinger, Maya
    Bubley, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [28] Randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC)
    Kim, Joseph W.
    McKay, Rana R.
    Taplin, Mary-Ellen
    Davis, Nancy B.
    Monk, Paul
    Appleman, Leonard Joseph
    Lara, Primo
    Vaishampayan, Ulka N.
    Zhang, Jingsong
    Paul, Asit K.
    Bubley, Glenn
    Van Allen, Eliezer Mendel
    Huang, Ying
    Zhang, Zhenwei
    Loda, Massimo
    Shapiro, Geoffrey
    LoRusso, Patricia
    Ivy, S. Percy
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [29] A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Patterson, Jesse Christopher
    Croucher, Peter
    Ridinger, Maya
    Erlander, Mark G.
    Yaffe, Michael B.
    Bubley, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [30] SHR3680, a novel antiandrogen, for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A phase I/II study
    Qin, Xiaojian
    Han, Weiqing
    Luo, Hong
    Du, Chuanjun
    Zou, Qing
    Sun, Zhongquan
    He, Chaohong
    Zhu, Shaoxing
    Chong, Tie
    Yao, Xin
    Wan, Ben
    Gu, Weijie
    Ye, Dingwei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345